Add to ORKGBackground: Evidence-based international guidelines for the treatment of systemic lupus ery-thematosus (SLE) recommend treatment with antimalarials (AMs) for all patients with SLE irrespective of disease activity. Only a few studies have investigated the use of AMs among newly diagnosed patients with SLE. Objectives: The objective of this paper is to analyze prescription patterns of AMs in newly diagnosed SLE patients in Denmark from 2000 t
The objectives of the study were to examine the initial, first-year anti-rheumatic outpatient therap...
Belimumab was the first biological drug approved for Systemic Lupus Erythematosus (SLE). There is no...
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease. It is characterized by a variab...
Background: Antimalarial agents (AMs), mainly hydroxychloroquine (HCQ) and chloroquine, are the corn...
Background: Antimalarial drugs (AMs), chloroquine (CQ) and hydroxychloroquine (HCQ), are frequently ...
Objective. To evaluate the beneficial effect of antimalarial treatment on lupus survival in a large,...
Objective. To evaluate the beneficial effect of antimalarial treatment on lupus survival in a large,...
Sooyoung Shin College of Pharmacy and Research Institute of Pharmaceutical Science and Technology (...
The ability of antimalarials to moderate severe disease activity in systemic lupus erythematosus (SL...
Introduction: This thesis comprises a systematic review and a pharmacoepidemiological study aimed at...
To analyze the long-term antimalarials (AM) usage on elderly systemic lupus erythematosus (SLE) pati...
This longitudinal retrospective study aims at describing the safety profile and the reasons for disc...
Outcomes for patients with systemic lupus erythematosus (SLE) have improved during the last two deca...
Erythematosus Systemic Lupus is a chronic inflammatory disease that affects about half a million Eur...
Antimalarial therapy has a long and successful track record in the management of patirents with mild...
The objectives of the study were to examine the initial, first-year anti-rheumatic outpatient therap...
Belimumab was the first biological drug approved for Systemic Lupus Erythematosus (SLE). There is no...
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease. It is characterized by a variab...
Background: Antimalarial agents (AMs), mainly hydroxychloroquine (HCQ) and chloroquine, are the corn...
Background: Antimalarial drugs (AMs), chloroquine (CQ) and hydroxychloroquine (HCQ), are frequently ...
Objective. To evaluate the beneficial effect of antimalarial treatment on lupus survival in a large,...
Objective. To evaluate the beneficial effect of antimalarial treatment on lupus survival in a large,...
Sooyoung Shin College of Pharmacy and Research Institute of Pharmaceutical Science and Technology (...
The ability of antimalarials to moderate severe disease activity in systemic lupus erythematosus (SL...
Introduction: This thesis comprises a systematic review and a pharmacoepidemiological study aimed at...
To analyze the long-term antimalarials (AM) usage on elderly systemic lupus erythematosus (SLE) pati...
This longitudinal retrospective study aims at describing the safety profile and the reasons for disc...
Outcomes for patients with systemic lupus erythematosus (SLE) have improved during the last two deca...
Erythematosus Systemic Lupus is a chronic inflammatory disease that affects about half a million Eur...
Antimalarial therapy has a long and successful track record in the management of patirents with mild...
The objectives of the study were to examine the initial, first-year anti-rheumatic outpatient therap...
Belimumab was the first biological drug approved for Systemic Lupus Erythematosus (SLE). There is no...
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease. It is characterized by a variab...